Multiple sclerosis
Conditions
Interventions
None listed
Sponsors
Immunic AG
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Countries
Netherlands
Outcome results
None listed
A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combination with Multiple Doses of Gemfibrozil as CYP2C8 Inhibitor, or Rifampicin as CYP2C8 Inducer, in Healthy Subjects
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: Feb 4, 2026